Daan Kromhout.

The survival rates in the GISSI-Prevenzione trial had been lower than those inside our study . Recently, not only provides there been improvement in survival however the causes of death have got shifted from cardiovascular to noncardiovascular causes.24 Finally, we cannot exclude the possibility that EPA and DHA experienced no therapeutic impact in sufferers who had experienced a myocardial infarction but whose condition was steady and who have been at relatively low risk for future cardiovascular events.‘Electronic surveillance [of the contents of hospital data systems] represents a cost-effective, time-efficient and robust approach to surveillance, although it is normally subjective to scientific opinion and a changing plan landscape,’ conclude co-authors and King. Licensed from medwireNews with permission from Springer Healthcare Ltd. All privileges reserved. Neither of these parties endorse or suggest any commercial products, services, or equipment.

AFFiRiS to commence Phase II trial of its Alzheimer’s vaccine candidate AFFiRiS AG will concentrate its Alzheimer’s vaccine program on one product candidate at an unexpectedly early stage of advancement: the vaccine candidate Advertisement02 is planned to enter Phase II clinical trial early in 2010 2010.